| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.03 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.067 | 0.03 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.085 | 0.04 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.069 | 0.04 |